Literature DB >> 1359395

kappa-Opioid inhibition of [3H]dopamine release from rat ventral mesencephalic dissociated cell cultures.

J A Smith1, S E Loughlin, F M Leslie.   

Abstract

The present study investigated the effect of opioids on [3H]dopamine release from mixed neuronal-glial cell cultures of embryonic rat ventral mesencephalon. Each of the major morphological types of dopaminergic cell was represented in these cultures. These cells exhibited specific uptake of [3H]dopamine, which was subsequently released, in a calcium-dependent manner, in response to a double pulse of elevated extracellular potassium. Spontaneous and potassium-evoked [3H]dopamine release was inhibited by kappa- but not mu- or delta-opioid agonists. The selective kappa 1 agonist (5 alpha, 7 alpha, 8 beta)-(-)-N-methyl-N-[7-(1-pyrollidinyl)-1-oxaspiro(4,5)- dec-8-yl]benzeneacetamide (U69593) produced a dose-dependent inhibition of dopamine release. The effect of U69593 was blocked by the nonselective opiate antagonist naloxone and the selective kappa opioid antagonist norbinaltorphimine. kappa-Opioid inhibition of potassium-evoked [3H]dopamine release was maintained in the presence of tetrodotoxin. These results suggest that functional kappa receptors, modulating dopamine release, are localized on the terminals of dopaminergic neurons.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1359395

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  6 in total

1.  Effect of the endogenous kappa opioid agonist dynorphin A(1-17) on cocaine-evoked increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6J mice.

Authors:  Yong Zhang; Eduardo R Butelman; Stefan D Schlussman; Ann Ho; Mary Jeanne Kreek
Journal:  Psychopharmacology (Berl)       Date:  2004-01-08       Impact factor: 4.530

2.  Kappa opioid inhibition of somatodendritic dopamine inhibitory postsynaptic currents.

Authors:  Christopher P Ford; Michael J Beckstead; John T Williams
Journal:  J Neurophysiol       Date:  2006-11-22       Impact factor: 2.714

3.  Kappa-opioid receptor activation modifies dopamine uptake in the nucleus accumbens and opposes the effects of cocaine.

Authors:  A C Thompson; A Zapata; J B Justice; R A Vaughan; L G Sharpe; T S Shippenberg
Journal:  J Neurosci       Date:  2000-12-15       Impact factor: 6.167

4.  Effect of the kappa opioid agonist R-84760 on cocaine-induced increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6J mice.

Authors:  Yong Zhang; Eduardo R Butelman; Stefan D Schlussman; Ann Ho; Mary Jeanne Kreek
Journal:  Psychopharmacology (Berl)       Date:  2004-01-08       Impact factor: 4.530

5.  Central and peripheral actions of the novel kappa-opioid receptor agonist, EMD 60400.

Authors:  A Barber; G D Bartoszyk; H E Greiner; F Mauler; R D Murray; C A Seyfried; M Simon; R Gottschlich; J Harting; I Lues
Journal:  Br J Pharmacol       Date:  1994-03       Impact factor: 8.739

6.  Endogenous kappa-opioid systems in opiate withdrawal: role in aversion and accompanying changes in mesolimbic dopamine release.

Authors:  R Spanagel; O F Almeida; C Bartl; T S Shippenberg
Journal:  Psychopharmacology (Berl)       Date:  1994-06       Impact factor: 4.530

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.